Journal of Parkinson s Disease,
Год журнала:
2024,
Номер
unknown, С. 1 - 18
Опубликована: Сен. 26, 2024
Inflammation
and
immune
dysregulation
have
been
linked
to
the
pathogenesis
progression
of
Parkinson’s
disease
(PD),
represent
an
attractive
target
for
therapeutic
intervention,
given
potential
repurposing
existing
anti-inflammatory
immunomodulatory
agents.
Despite
fact
that
initial
studies
drugs
with
secondary
effects
did
not
yield
positive
results,
agents
specifically
targeting
inflammatory
pathways
may
hold
more
promise.
This
article
will
briefly
review
evidence
base
system
neuroinflammation
in
PD,
discuss
detail
recently
completed
currently
active
trials
primary
anti-inflammatory/immunomodulatory
PD.
Journal of Neuroimmunology,
Год журнала:
2023,
Номер
382, С. 578154 - 578154
Опубликована: Июль 24, 2023
Immune
dysregulation
is
heavily
implicated
in
Parkinson's
disease
(PD)
but
the
role
of
Natural
Killer
(NK)
cells
has
not
been
well
characterised.
Accumulating
evidence
indicates
immune
response
peaks
early
disease,
hence
this
study
focused
on
characterising
NK
recently
diagnosed
PD.
PBMCs
were
obtained
from
PD
cases
(<
2
years
duration)
and
age-matched
controls
immunophenotyped
using
flow
cytometry.
We
found
an
increased
proportion
number
(CD3-CD56+),
mature
cytotoxic
(CD3-CD16
+
CD56dim),
expressing
activation
marker,
NKG2D.
This
implies
are
activated
earliest
stages
Journal of Neurophysiology,
Год журнала:
2024,
Номер
131(6), С. 1115 - 1125
Опубликована: Май 1, 2024
In
this
study,
based
on
the
GWAS
Immunophenotyping
Database,
a
Mendelian
randomization
approach
was
used
to
assess
genetic
causal
associations
between
731
immunophenotypes
and
traits
Parkinson’s
disease
(PD),
which
not
only
provides
reference
for
immune
response
mechanism
of
PD
but
also
ideas
exploring
effective
diagnosis
treatment
PD.
Journal of Neurology,
Год журнала:
2024,
Номер
271(9), С. 5916 - 5929
Опубликована: Июль 10, 2024
Parkinson's
disease
displays
clinical
heterogeneity,
presenting
with
motor
and
non-motor
symptoms.
Heterogeneous
phenotypes,
named
brain-first
body-first,
may
reflect
distinct
α-synuclein
pathology
starting
either
in
the
central
nervous
system
or
periphery.
The
immune
plays
a
prominent
role
peripheral
pathology,
misfolded
being
placed
at
intersection
between
neurodegeneration
inflammation.
Here,
we
characterized
inflammatory
profile
immune-phenotype
of
blood
mononuclear
cells
(PBMCs)
from
patients
upon
stimulation
monomer
oligomer,
investigated
relationships
parameters
scores
Freshly
isolated
PBMCs
21
18
healthy
subjects
were
exposed
vitro
to
species.
Cytokine/chemokine
release
was
measured
culture
supernatant
by
Multiplex
Elisa.
studied
FACS-flow
cytometry.
Correlation
analysis
computed
parkinsonian
scales.
We
found
that
exhibited
dysregulated
PBMC-cytokine
profile,
which
remained
unaltered
after
exposure
species
correlated
both
severity,
strong
correlation
observed
olfactory
impairment.
Exposure
controls
monomer/oligomer
increased
cytokine/chemokine
up
patient's
values.
Moreover,
phenotype
differed
revealed
association
Mos
impairment,
NK
constipation.
Results
suggest
deranged
PBMC-immune
subtypes
would
fit
recent
classification
into
peripheral-first
versus
phenotype.
Journal of Parkinson s Disease,
Год журнала:
2024,
Номер
unknown, С. 1 - 18
Опубликована: Сен. 26, 2024
Inflammation
and
immune
dysregulation
have
been
linked
to
the
pathogenesis
progression
of
Parkinson’s
disease
(PD),
represent
an
attractive
target
for
therapeutic
intervention,
given
potential
repurposing
existing
anti-inflammatory
immunomodulatory
agents.
Despite
fact
that
initial
studies
drugs
with
secondary
effects
did
not
yield
positive
results,
agents
specifically
targeting
inflammatory
pathways
may
hold
more
promise.
This
article
will
briefly
review
evidence
base
system
neuroinflammation
in
PD,
discuss
detail
recently
completed
currently
active
trials
primary
anti-inflammatory/immunomodulatory
PD.
